

Antimicrobial Peptides as Potential Anti-Tubercular

Subjects: Infectious Diseases

Contributor: Cátia Teixeira

Antimicrobial peptides (AMP) are small cationic and amphipathic molecules that play a vital role in the host immune system by acting as a first barrier against invading pathogens. The broad spectrum of properties that peptides possess make them one of the best possible alternatives for a new “post-antibiotic” era.

Keywords: antimicrobial peptides ; anti-tubercular drugs ; antibiotic resistance ; mycobacteria ; tuberculosis

1. Antimicrobial Peptides as a New Tool to Tackle Antibiotic-Resistant Infections

Antimicrobial peptides (AMP, also known as host defense peptides) are essential components of the innate immune system and possess broad-spectrum activities such as antimicrobial, wound-healing, immunomodulatory and antibiofilm. They have shown to be promising drug candidates for the treatment of microbial infections, either as a monotherapy or in conjugation with other pre-existing drugs ^{[1][2][3][4]}.

Several models have been proposed to describe the pathways through which AMP exert their antimicrobial action ^[5] and it is well known that AMP can act through different mechanisms (Figure 1). This has a major impact on their high efficacy and the broad spectrum of activity, including Gram-positive and Gram-negative bacteria, but also fungi, viruses, unicellular protozoa, and cancer cells ^[6]. For instance, AMP can disrupt the membrane through pore and micelles formation, binding with specific receptors or through electroporation. Moreover, they can induce cell death through interaction with internal cellular components, hijacking important processes vital to the pathogens. They can also interfere with the cell wall through inhibition of its biosynthesis. Lastly, they are capable of exerting antimicrobial activity without ever interacting with the pathogens, through modulation of the innate immune system ^{[5][6][7][8][9]}. Remarkably, the paradigm of how peptides act is in constant change. It is now clear that several peptides are capable of exerting activity through various mechanisms. Importantly, this may hinder the development of anti-AMP resistance.




Figure 1. Some of the bacterial molecular targets of AMP: (A) bacterial cell wall; (B) bacterial membrane; (C) DNA synthesis; (D) DNA replication; (E) key bacterial protein synthesis. Some of the effects of AMP on host immune cells: (F) induction of autophagy on infected cells; (G) Overexpression of pro- and anti-inflammatory cytokines; (H) Chemotaxis' induction ^{[10][11]}.

2. Animal AMP with Anti-Tubercular Activity

2.1. Cathelicidins

Cathelicidins are a family of mammalian AMP with approximately 30 identified members. However, in humans, rhesus monkeys, rats, mice, and guinea pigs, only a single cathelicidin is expressed, named LL-37, RL-37, rCRAMP, mCRAMP, and CAP11, respectively in each species. The peptide is produced in different cells, most notably in neutrophils, in response to an infection [12].

2.2. Human Defensins

Defensins are small cationic peptides with broad-spectrum activity against bacteria, viruses, and fungi, predominantly expressed in epithelial cells and neutrophils. They inhibit bacterial growth through various mechanisms, depending on the defensin itself and its target. Nonetheless, direct cell membrane disruption and targeting of DNA are two pathways commonly observed. They also exert antibacterial activities through neutralization of secreted toxins and are responsible for chemotaxis [13][14][15].

2.3. Protegrins

The protegrins family is composed of five native AMP sequences identified in porcine leukocytes (PG-1 to PG-5) [16]. These cationic peptides are 16 to 18 amino acids long, and adopt amphipathic β -sheet structure [17][18]. Against axenically growing *Mtb* H37Rv, PG-1 displayed a 68.4% CFU reduction at 64 $\mu\text{g/mL}$ and 96.7% 128 $\mu\text{g/mL}$, whereas against an MDR strain a significant decrease is only achieved at 128 $\mu\text{g/mL}$ (Table 1). Nonetheless, the peptide displayed a synergistic effect when administered alongside isoniazid [19].

2.4. Hepcidin

Hepcidin is an AMP involved in iron homeostasis. Iron is extremely important for all living organisms, including bacteria, participating in major biological processes such as gene regulation and DNA biosynthesis [20]. It is also required to produce superoxide dismutase which protects them from the hosts' oxygen radicals [21].

2.5. Lactoferrin

Lactoferrin (LF) is an 80 kDa iron-binding glycoprotein present in various mammalian secretions, such as saliva, tears, and milk. Its affinity for iron is 300 times higher than serum transferrin [22]. Possessing a wide array of physiological functions such as antimicrobial and immunomodulatory, it plays a significant role in the innate immune system, being associated with host defence against oral pathogens, given its presence in saliva. Several peptides with antimicrobial activities are produced by the action of proteases on LF [23].

2.6. Ub2—A Ubiquitin-Derived Peptide

Ubiquitin is a protein that regulates proteasomal degradation, marking its target proteins to be destroyed in the 26S proteasome [24]. Moreover, ubiquitin is responsible for regulating the trafficking of proteins in the endocytic pathway [25]. During an infection, the fusion of the phagosome with the lysosome facilitates the killing of the invading pathogen through both oxidative and non-oxidative mechanisms. Ubiquitin-derived peptides are the primary mediators of those non-oxidative mechanisms [26]. Ubiquitin itself has no antimycobacterial activity in lysosomal extracts. However, some of its derived peptides produced by proteolytic degradation of ubiquitin, namely Ub2, are active [27].

2.7. Hcl2

Hcl2 is a fragment of the human mitochondrial protein COX3. It was reported to strongly bind ESAT-6 [28], a protein secreted by *Mtb* that plays a key role in the mycobacterial pathogenesis, by suppressing the antigen presentation of macrophages [29].

2.8. Cathepsin G-Derived Peptides

Cathepsin G (catG) is a neutrophil serine protease (NSP) with antimicrobial properties. Stored within the acidic granules, NSP become active only after being released into the phagocytic vacuole. Furthermore, they are also components of neutrophil extracellular traps—extracellular fibrillary structures released by neutrophils. These traps are composed of NSP alongside chromatin and facilitate pathogen arrest [30][31].

2.9. Venom-Derived Peptides

Natural toxins can be used therapeutically against several diseases, due to their high specificity for certain cellular components. Scorpion venom has been studied as a source of those toxins, as it is a mixture of polypeptides, nucleotides, mucoproteins among other substances [32]. Their AMP share relevant characteristics with the ones we are typically familiar with, such as the presence of hydrophobic and cationic residues, a positive net charge, and the ability to adopt an amphipathic structure [33].

2.10. B1CTcu5

B1CTcu5 is a 21-amino acids long AMP that belongs to the Brevinin-1 family, sharing a very similar sequence to its parental peptide. Brevinins are known for their antimicrobial activities against Gram-positive and Gram-negative bacteria. This cationic peptide was isolated from the skin secretion of the frog *Clinotarsus curtipes* [34][35]. Against planktonic cultures of *Mtb* H37Rv this peptide was bactericidal, presenting a MIC of 12.5 µg/mL. Moreover, at its MIC, the peptide was capable of completely inhibiting *Mtb* growing inside THP1-derived macrophages. Furthermore, it was deemed as non-toxic against this cell line, proving to be a potential anti-tubercular lead [35].

3. Non-Animal AMPs with Anti-Tubercular Activity

3.1. Bacterial Peptides

Nisin A and lacticin 3147 are two of the best characterized lantibiotics. Ribosomally synthesized peptides produced by the Gram-positive bacteria *Lactococcus lactis*, lantibiotics have had their use well-documented in food, animal, and human applications [36]. Mutacin 1140, typically known as MU1140, is derived from *Streptococcus mutans* JH1140, has 22 amino acids and presents low levels of toxicity, a high degree of stability, and good pharmacokinetics [37][38]. Lasso peptides are a subclass of ribosomally synthesized and post-translationally modified peptides characterized by a stable structure. With a broad spectrum of bioactivity, lasso peptides have been associated with antimicrobial action, including relevant anti-tubercular efficacy [39]. *Streptomyces* has been a bacterial source of peptides with antimycobacterial properties [40]. Most importantly, these bacteria are the source of streptomycin, the first approved antibiotic used to treat tuberculosis [41].

3.2. Fungal Peptides

Fungal defensins are potent AMP with low toxicity and high serum stability. Through the method of residue substitution, several variants of plecostasin were generated such as NZX, with reported anti-tubercular activities and high resistance to proteases' action [42]. Trichodermin A, the peptide with the highest efficacy, was found to exert this potent antimycobacterial activity through inhibition of the mycobacterial ATP synthesis [43].

3.3. Plant-Derived Peptides

Capsicum plants, specifically, have been considered as a possible research target in the search for new proteins and peptides that help defend plants against invading pathogens, given their already described antibacterial compounds [44][45].

4. Taking AMPs from Bench to the Clinic

However, despite their remarkable properties, AMPs still face major challenges to join the pharmaceutical industry. The primary challenge is the susceptibility to proteolytic enzymes. When administered orally, AMP must overcome enzymes that operate through the digestive tract, like pepsin, trypsin, and chymotrypsin. Intravenous administration poses similar challenges, as there are many proteases in blood [46]. Moreover, intravenous administration translates into a shorter half-life due to hepatic and renal clearances [47]. New design strategies have been applied to overcome these challenges, with the incorporation of non-natural amino acids, backbone mimetics, conjugation with fatty acids, and *N* and *C*-terminus modifications [48]. Furthermore, drug delivery systems, using different types of vehicles such as nanoparticles, liposomes, or different gel formulations, have also been a strategy employed to reduce proteolytic degradation [49].

References

1. Haney, E.F.; Straus, S.K.; Hancock, R.E.W. Reassessing the Host Defense Peptide Landscape. *Front. Chem.* 2019, 7, 43.

2. Padhi, A.; Sengupta, M.; Sengupta, S.; Roehm, K.H.; Sonawane, A. Antimicrobial peptides and proteins in mycobacterial therapy: Current status and future prospects. *Tuberculosis* 2014, 94, 363–373.
3. Magana, M.; Pushpanathan, M.; Santos, A.L.; Leanse, L.; Fernandez, M.; Ioannidis, A.; Giulianotti, M.A.; Apidianakis, Y.; Bradfute, S.; Ferguson, A.L.; et al. The value of antimicrobial peptides in the age of resistance. *Lancet Infect. Dis.* 2020, 20, e216–e230.
4. Gaglione, R.; Pizzo, E.; Notomista, E.; de la Fuente-Nunez, C.; Arciello, A. Host Defence Cryptides from Human Apolipoproteins: Applications in Medicinal Chemistry. *Curr. Top. Med. Chem.* 2020, 20, 1324–1337.
5. Hancock, R.E.; Sahl, H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat. Biotechnol.* 2006, 24, 1551–1557.
6. Nguyen, L.T.; Haney, E.F.; Vogel, H.J. The expanding scope of antimicrobial peptide structures and their modes of action. *Trends Biotechnol.* 2011, 29, 464–472.
7. Kumar, P.; Kizhakkedathu, J.N.; Straus, S.K. Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo. *Biomolecules* 2018, 8, 4.
8. Zasloff, M. Antimicrobial peptides of multicellular organisms. *Nature* 2002, 415, 389–395.
9. Silva, T.; Gomes, M.S. Immuno-Stimulatory Peptides as a Potential Adjunct Therapy against Intra-Macrophagic Pathogens. *Molecules* 2017, 22, 1297.
10. Lei, J.; Sun, L.; Huang, S.; Zhu, C.; Li, P.; He, J.; Mackey, V.; Coy, D.H.; He, Q. The antimicrobial peptides and their potential clinical applications. *Am. J. Transl. Res.* 2019, 11, 3919–3931.
11. Hemshekhar, M.; Anaparti, V.; Mookherjee, N. Functions of Cationic Host Defense Peptides in Immunity. *Pharmaceuticals* 2016, 9, 40.
12. Kosciuczuk, E.M.; Lisowski, P.; Jarczak, J.; Strzalkowska, N.; Jozwik, A.; Horbanczuk, J.; Krzyzewski, J.; Zwierzchowski, L.; Bagnicka, E. Cathelicidins: Family of antimicrobial peptides. A review. *Mol. Biol. Rep.* 2012, 39, 10957–10970.
13. Xu, D.; Lu, W. Defensins: A Double-Edged Sword in Host Immunity. *Front. Immunol.* 2020, 11, 764.
14. Dong, H.; Lv, Y.; Zhao, D.; Barrow, P.; Zhou, X. Defensins: The Case for Their Use against Mycobacterial Infections. *J. Immunol. Res.* 2016, 2016, 7515687.
15. Amerikova, M.; Pencheva El-Tibi, I.; Maslarska, V.; Bozhanov, S.; Tachkov, K. Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents. *Biotechnol. Equip.* 2019, 33, 671–682.
16. Zhao, C.; Ganz, T.; Lehrer, R.I. The structure of porcine protegrin genes. *FEBS Lett.* 1995, 368, 197–202.
17. Fahrner, R.L.; Dieckmann, T.; Harwig, S.S.; Lehrer, R.I.; Eisenberg, D.; Feigon, J. Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide from porcine leukocytes. *Chem. Biol.* 1996, 3, 543–550.
18. Aumelas, A.; Mangoni, M.; Roumestand, C.; Chiche, L.; Despau, E.; Grassy, G.; Calas, B.; Chavanieu, A. Synthesis and solution structure of the antimicrobial peptide protegrin-1. *Eur. J. Biochem.* 1996, 237, 575–583.
19. Fattorini, L.; Gennaro, R.; Zanetti, M.; Tan, D.; Brunori, L.; Giannoni, F.; Pardini, M.; Orefici, G. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against *Mycobacterium tuberculosis*. *Peptides* 2004, 25, 1075–1077.
20. Andrews, S.C.; Robinson, A.K.; Rodriguez-Quinones, F. Bacterial iron homeostasis. *FEMS Microbiol. Rev.* 2003, 27, 215–237.
21. Malyszko, J.; Tesar, V.; Macdougall, I.C. Neutrophil gelatinase-associated lipocalin and hepcidin: What do they have in common and is there a potential interaction? *Kidney Blood Press Res.* 2010, 33, 157–165.
22. Caccavo, D.; Pellegrino, N.M.; Altamura, M.; Rigon, A.; Amati, L.; Amoroso, A.; Jirillo, E. Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. *J. Endotoxin Res.* 2002, 8, 403–417.
23. Bruni, N.; Capucchio, M.T.; Biasibetti, E.; Pessione, E.; Cirrincione, S.; Giraudo, L.; Corona, A.; Dosio, F. Antimicrobial Activity of Lactoferrin-Related Peptides and Applications in Human and Veterinary Medicine. *Molecules* 2016, 21, 752.
24. Komander, D.; Rape, M. The ubiquitin code. *Annu. Rev. Biochem.* 2012, 81, 203–229.
25. Hicke, L.; Schubert, H.L.; Hill, C.P. Ubiquitin-binding domains. *Nat. Rev. Mol. Cell Biol.* 2005, 6, 610–621.
26. Teng, T.; Liu, J.; Wei, H. Anti-mycobacterial peptides: From human to phage. *Cell. Physiol. Biochem.* 2015, 35, 452–466.

27. Alonso, S.; Pethe, K.; Russell, D.G.; Purdy, G.E. Lysosomal killing of *Mycobacterium* mediated by ubiquitin-derived peptides is enhanced by autophagy. *Proc. Natl. Acad. Sci. USA* 2007, 104, 6031–6036.
28. Samuchiwal, S.K.; Tousif, S.; Singh, D.K.; Kumar, A.; Ghosh, A.; Bhalla, K.; Prakash, P.; Kumar, S.; Bhattacharyya, M.; Moodley, P.; et al. A peptide fragment from the human COX3 protein disrupts association of *Mycobacterium tuberculosis* virulence proteins ESAT-6 and CFP10, inhibits mycobacterial growth and mounts protective immune response. *BMC Infect. Dis.* 2014, 14, 355.
29. Sreejit, G.; Ahmed, A.; Parveen, N.; Jha, V.; Valluri, V.L.; Ghosh, S.; Mukhopadhyay, S. The ESAT-6 protein of *Mycobacterium tuberculosis* interacts with beta-2-microglobulin (beta2M) affecting antigen presentation function of macrophage. *PLoS Pathog.* 2014, 10, e1004446.
30. Stapels, D.A.; Geisbrecht, B.V.; Rooijackers, S.H. Neutrophil serine proteases in antibacterial defense. *Curr. Opin. Microbiol.* 2015, 23, 42–48.
31. Mutua, V.; Gershwin, L.J. A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics. *Clin. Rev. Allergy Immunol.* 2020.
32. Hmed, B.; Serria, H.T.; Mounir, Z.K. Scorpion peptides: Potential use for new drug development. *J. Toxicol.* 2013, 2013, 958797.
33. Ramirez-Carreto, S.; Jimenez-Vargas, J.M.; Rivas-Santiago, B.; Corzo, G.; Possani, L.D.; Becerril, B.; Ortiz, E. Peptides from the scorpion *Vaejovis punctatus* with broad antimicrobial activity. *Peptides* 2015, 73, 51–59.
34. Morikawa, N.; Hagiwara, K.; Nakajima, T. Brevinin-1 and -2, unique antimicrobial peptides from the skin of the frog, *Rana brevipoda porsa*. *Biochem. Biophys. Res. Commun.* 1992, 189, 184–190.
35. Abraham, P.; Jose, L.; Maliekal, T.T.; Kumar, R.A.; Kumar, K.S. B1CTcu5: A frog-derived brevinin-1 peptide with anti-tuberculosis activity. *Peptides* 2020, 132, 170373.
36. Donaghy, J. Lantibiotics as prospective antimycobacterial agents. *Bioeng. Bugs* 2010, 1, 437–439.
37. Ghobrial, O.; Derendorf, H.; Hillman, J.D. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. *J. Pharm. Sci.* 2010, 99, 2521–2528.
38. Hillman, J.D.; Novak, J.; Sagura, E.; Gutierrez, J.A.; Brooks, T.A.; Crowley, P.J.; Hess, M.; Azizi, A.; Leung, K.; Cvitkovitch, D.; et al. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from *Streptococcus mutans*. *Infect. Immun.* 1998, 66, 2743–2749.
39. Zhu, S.; Su, Y.; Shams, S.; Feng, Y.; Tong, Y.; Zheng, G. Lassomycin and lariatin lasso peptides as suitable antibiotics for combating mycobacterial infections: Current state of biosynthesis and perspectives for production. *Appl. Microbiol. Biotechnol.* 2019, 103, 3931–3940.
40. Shoji, J.; Sakazaki, R. A new peptide antibiotic complex S-520. II. Further characterization and degradative studies. *J. Antibiot.* 1970, 23, 432–436.
41. Cohen, K.A.; Stott, K.E.; Munsamy, V.; Manson, A.L.; Earl, A.M.; Pym, A.S. Evidence for Expanding the Role of Streptomycin in the Management of Drug-Resistant *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* 2020, 64.
42. Tenland, E.; Krishnan, N.; Ronnholm, A.; Kalsum, S.; Puthia, M.; Morgelin, M.; Davoudi, M.; Otrocka, M.; Alaridah, N.; Glegola-Madejska, I.; et al. A novel derivative of the fungal antimicrobial peptide plectasin is active against *Mycobacterium tuberculosis*. *Tuberculosis* 2018, 113, 231–238.
43. Pruksakorn, P.; Arai, M.; Liu, L.; Moodley, P.; Jacobs, W.R., Jr.; Kobayashi, M. Action-mechanism of trichoderin A, an anti-dormant mycobacterial aminolipopeptide from marine sponge-derived *Trichoderma* sp. *Biol. Pharm. Bull.* 2011, 34, 1287–1290.
44. Koffi-Nevry, R.; Kouassi, K.C.; Nanga, Z.Y.; Koussémon, M.; Loukou, G.Y. Antibacterial Activity of Two Bell Pepper Extracts: *Capsicum annuum* L. and *Capsicum frutescens*. *Int. J. Food Prop.* 2012, 15, 961–971.
45. Santos, M.M.; Vieira-da-Motta, O.; Vieira, I.J.; Braz-Filho, R.; Goncalves, P.S.; Maria, E.J.; Terra, W.S.; Rodrigues, R.; Souza, C.L. Antibacterial activity of *Capsicum annuum* extract and synthetic capsaicinoid derivatives against *Streptococcus mutans*. *J. Nat. Med.* 2012, 66, 354–356.
46. Haney, E.F.; Hancock, R.E. Peptide design for antimicrobial and immunomodulatory applications. *Biopolymers* 2013, 100, 572–583.
47. Mahlapuu, M.; Hakansson, J.; Ringstad, L.; Bjorn, C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. *Front. Cell. Infect. Microbiol.* 2016, 6, 194.
48. Costa, F.; Teixeira, C.; Gomes, P.; Martins, M.C.L. Clinical Application of AMPs. *Adv. Exp. Med. Biol.* 2019, 1117, 281–298.

49. Martin-Serrano, A.; Gomez, R.; Ortega, P.; de la Mata, F.J. Nanosystems as Vehicles for the Delivery of Antimicrobial Peptides (AMPs). *Pharmaceutics* 2019, **11**, 448.
-

Retrieved from <https://encyclopedia.pub/entry/history/show/24222>